Bipartisan Support For Drug Transparency Bill Raises Hopes of Passage | The Lund Report

A scaled back version of a 2017 bill that sought to cap drug costs will instead follow a route successful in California, requiring drug manufacturers to explain big price increases
Chris Gray

Rep. Rob Nosse, D-Portland, has found bipartisan, bicameral support for legislation to improve the price transparency for pharmaceuticals, giving momentum to passage that eluded advocates last year.

The 2018 proposal is heavily scaled back from Nosse’s 2017 legislation, which would have set caps on how much drugmakers could charge or increase prices. House Bill 2387 passed the House Health Committee on a party-line vote, but floundered in the budget committee and never reached the floor.

Last year’s debate pitted the health insurance lobby and consumer advocates like AARP and the Oregon State Public Interest Research Group against the Pharmaceutical Research and Manufacturers of America, which won out, despite the runaway costs of drugs, one of the leading causes of medical inflation.

But since then, California was able to enact a law that forces drugmakers to explain and give notice when they hike drug prices, and now Sen. Dennis Linthicum, R-Klamath Falls, and Rep. Ron Noble, R-McMinnville, are willing to back House Bill 4005, the new transparency measure which forces drugmakers to provide similar information to Oregon state officials.

Read complete article here:

Bipartisan Support For Drug Transparency Bill Raises Hopes of Passage | The Lund Report.